 | |
| Discipline | Pharmacology |
|---|---|
| Language | English |
| Publication details | |
| History | 2006-present |
| Publisher | |
| Frequency | Monthly |
| 3.846 (2016) | |
| Standard abbreviations | |
| ISO 4 | Expert Opin. Drug Discov. |
| Indexing | |
| CODEN | EODDBX |
| ISSN | 1746-0441 |
| Links | |
Expert Opinion on Drug Discovery is a monthly peer-reviewed medical journal publishing review articles on novel technologies involved in drug discovery. The editor-in-chief is David Janero from Northeastern University.
The journal is abstracted and indexed in Chemical Abstracts, EMBASE/Excerpta Medica, and Science Citation Index Expanded.
  | This article about a pharmacology journal is a stub. You can help Wikipedia by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page. |
Pharmacology is a branch of medicine, biology, and pharmaceutical sciences concerned with drug or medication action, where a drug may be defined as any artificial, natural, or endogenous molecule which exerts a biochemical or physiological effect on the cell, tissue, organ, or organism. It is the science of drugs including their origin, composition, pharmacokinetics, therapeutic use, and toxicology. More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.
A medication is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy (pharmacotherapy) is an important part of the medical field and relies on the science of pharmacology for continual advancement and on pharmacy for appropriate management.
The therapeutic index is a quantitative measurement of the relative safety of a drug. It is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxicity. The related terms therapeutic window or safety window refer to a range of doses optimized between efficacy and toxicity, achieving the greatest therapeutic benefit without resulting in unacceptable side-effects or toxicity.
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it. Drug design frequently but not necessarily relies on computer modeling techniques. This type of modeling is sometimes referred to as computer-aided drug design. Finally, drug design that relies on the knowledge of the three-dimensional structure of the biomolecular target is known as structure-based drug design. In addition to small molecules, biopharmaceuticals including peptides and especially therapeutic antibodies are an increasingly important class of drugs and computational methods for improving the affinity, selectivity, and stability of these protein-based therapeutics have also been developed.
Ergometrine, also known as ergonovine and sold under the brand names Ergotrate, Ergostat, and Syntometrine among others, is a medication used to cause contractions of the uterus to treat heavy vaginal bleeding after childbirth. It can be used either by mouth, by injection into a muscle, or injection into a vein. It begins working within 15 minutes when taken by mouth and is faster in onset when used by injection. Effects last between 45 and 180 minutes.
A structural analog, also known as a chemical analog or simply an analog, is a compound having a structure similar to that of another compound, but differing from it in respect to a certain component.
Drug Discovery Today is a monthly peer-reviewed scientific journal that is published by Elsevier. It was established in 1996 and publishes reviews on all aspects of preclinical drug discovery from target identification and validation through hit identification, lead identification and optimisation, to candidate selection.
Embase is a biomedical and pharmacological bibliographic database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug. Embase, produced by Elsevier, contains over 32 million records from over 8,500 currently published journals from 1947 to the present. Through its international coverage, daily updates, and drug indexing with EMTREE, Embase enables tracking and retrieval of drug information in the published literature. Each record is fully indexed and Articles in Press are available for some records and In Process are available for all records, ahead of full indexing. Embase's international coverage expands across biomedical journals from 95 countries and is available through a number of database vendors.
Nature Reviews Drug Discovery is a monthly peer-reviewed review journal published by Nature Portfolio. It was established in 2002 and covers drug discovery and development. The editor-in-chief is Peter Kirkpatrick. According to the Journal Citation Reports, the journal has a 2021 impact factor of 112.288, ranking it 1st out of 158 journals in the category "Biotechnology & Applied Microbiology" and 1st out of 279 journals in the category "Pharmacology & Pharmacy".
Science Signaling is a peer-reviewed scientific journal that is focused on cell signaling and regulation. It is published weekly by the American Association for the Advancement of Science (AAAS). The editor-in-chief is Michael B. Yaffe, and the journal is part of the Science Family of Journals of which Holden Thorp is the Editor-in-Chief.
EmBiology is a bibliographic database established in June 2005, and produced by Elsevier. EmBiology focuses on indexing the literature in the life sciences in general. Coverage includes science in the laboratory and science in the field. It is designed to be smaller than EMBASE, with abstracting and indexing for 1,800 journals not covered by the larger database. However, there is some overlap. Hence, EmBiology is specifically designed for academic institutions that range from small to mid-size and all biotechnology and pharmaceutical companies.
SLAS Discovery is a peer-reviewed scientific journal published by the Society for Laboratory Automation and Screening (SLAS) in partnership with SAGE Publications. The editor-in-chief is Robert M. Campbell, Ph.D.. The journal explores how scientists develop and utilize novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. This includes scientific and technical advances in target identification/validation; biomarker discovery; assay development; virtual, medium- or high-throughput screening; lead generation/optimization; chemical biology; and informatics. The journal was published from 1996 through 2016 with the title Journal of Biomolecular Screening. Its name changed in 2017 to more accurately reflect the evolution of its editorial scope.[1]
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang. The journal covers research on contemporary molecular drug targets involved in cancer, including medicinal chemistry, pharmacology, molecular biology, genomics, and biochemistry. Current Cancer Drug Targets publishes original research reports, review papers, and rapid communications ("letters").
Phenotypic screening is a type of screening used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell or an organism in a desired manner. Phenotypic screening must be followed up with identification and validation, often through the use of chemoproteomics, to identify the mechanisms through which a phenotypic hit works.
Future Medicinal Chemistry is a peer-reviewed medical journal covering all aspects of medicinal chemistry, including drug discovery, pharmacology, in silico drug design, structural characterization techniques, ADME-Tox investigations, and science policy, economic and intellectual property issues. It was established in 2009 and is published by Future Science. The editors-in-chief are Iwao Ojima and Jonathan Baell.
L-4-Chlorokynurenine is an orally active small molecule prodrug of 7-chlorokynurenic acid, a NMDA receptor antagonist. It was investigated as a potential rapid-acting antidepressant.
Flumezapine is an abandoned, investigational antipsychotic drug that was studied for the treatment of schizophrenia. Flumezapine failed clinical trials due to concern for liver and muscle toxicity. Flumezapine is structurally related to the common antipsychotic olanzapine—a point that was used against its manufacturer, Eli Lilly and Company, in a lawsuit in which generic manufacturers sought to void the patent on brand name olanzapine (Zyprexa). Although flumezapine does not differ greatly from olanzapine in terms of its structure, the difference was considered to be non-obvious, and Eli Lilly's patent rights on Zyprexa were upheld.
Anti-Cancer Agents in Medicinal Chemistry is a peer-reviewed academic journal covering the disciplines of medicinal chemistry and drug design relating to chemotherapeutic agents in cancer. It is published by Bentham Science Publishers and the editor-in-chief is Simone Carradori. The journal covers developments in "medicinal chemistry and rational drug design for the discovery of anti-cancer agents" and publishes original research reports and review papers.
